Akebia Therapeutics Inc 2024年度报告

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (MarkOne) For thefiscal year endedDecember 31, 2024 For the transion period from _to_ Commission File Number001-36352 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Registrant’s telephone number, including area code: (617)871-2098 Securies registered pursuant to Secon12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule405 of the Securies Act.Yes☐No☒ Indicate by check mark if the registrant is not required tofile reports pursuant to Secon13 or 15(d) of the Act.Yes☐No☒ Indicate by check mark whether the registrant: (1)hasfiled all reports required to befiled by Secon13 or 15(d) of the Securies Exchange Act of 1934 during thepreceding 12months (or for such shorter period that the registrant was required tofile such reports), and (2)has been subject to suchfiling requirements for the past90days.Yes☒No☐ Indicate by check mark whether the registrant has submied electronically every Interacve Data File required to be submied pursuant to Rule405 of RegulaonS-T(§ 232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant was required to submit suchfiles).Yes☒No☐ Indicate by check mark whether the registrant is a large acceleratedfiler, an acceleratedfiler, a non-acceleratedfiler, a smaller reporng company, or an emerginggrowth company. See the definions of “large acceleratedfiler,” “acceleratedfiler,” “smaller reporng company,” and “emerging growth company” in Rule12b-2 of theExchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transion period for complying with any new or revisedfinancial accounng standards provided pursuant to Secon 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant hasfiled a report on and aestaon to its management’s assessment of the effecveness of its internal control overfinancial reporng under Secon 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounngfirm that prepared or issued its audit report.☒ If securies are registered pursuant to Secon 12(b) of the Act, indicate by check mark whether thefinancial statements of the registrant included in thefiling reflectthe correcon of an error to previously issuedfinancial statements.☐ Indicate by check mark whether any of those error correcons are restatements that required a recovery analysis of incenve-based compensaon received by any ofthe registrant’s execuve officers during the relevant recovery period pursuant to § 240.10D-1(b).☐ Indicate by check mark whether registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No☒ The aggregate market value of the vong and non-vong common equity held by non-affiliates of the registrant, based on the closing price of the registrant’s CommonStock on The Nasdaq Capital Market on June 28, 2024, was $210,916,948. The number of shares of registrant’s Common Stock outstanding as of March10, 2025 was236,231,057. DOCUMENTS INCORPORATED BY REFERENCE The registrant intends tofile a definive proxy statement pursuant to Regulaon 14A in connecon with its 2025Annual Meeng of Stockholders within 120 days aerthe end of the registrant’sfiscal year ended December31, 2024. Porons of the proxy statement are incorporated by reference into PartIII of this Annual Report onForm 10-K. Akebia Therapeucs, Inc.Form 10-KFor the Year Ended December 31, 2024 TABLE OF CONTENTS PageCauonary Note Regarding Forward Looking Statements2Risk Factors Summary4PART IItem1.Business6Item1A.Risk Factors49Item1B.Unresolved StaffComments105Item 1C.Cybersecurity105Item2.Properes107Item3.Legal Proceedings107Item4.Mine Safety Disclosures107PART IIItem5.Market for Registrant’s Common Equity, Related Stockholder Maers and Issuer Purchases of Equity Securies108Item6.[Reserved]108Item7.Management’s Discussionand Analysis of Financial Condion and Results of Operaons108Item7A.Quantave and Qualitave Disclosures About Market Risk122Item8.Financial Statements and Supplementary Data123Item9.Changes in and Disagreements with Accountants on Accounng and Financial Disclosure164Item9A.Controls and Procedures165Item9B.Other Informaon167Item 9C.Disclosure Regarding Foreign Jurisdicons that Prevent Inspecons167PART IIIItem10.Directors, Execuve Officers and Corporate Governance168Item11.Execuve Compensaon168Item12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Maers168Item13.Certain Relaonships and Related Transacons, and Director Independence168Item14.Principal Accountant Fees and Services168PARTIV169Item15.Exhibits and Financial Statement Schedules169Item16.Form 10-K Summary178SIGNATURES179 In this Annual Report on Form 10-K, orForm 10-K, unless otherwise stated or the context otherwise requires, references